2002;20:183C194. cancer. 2004, 2007, Abstract # 89. 5Sanborn, S. L.; Cooney, M.; Gibbons, J.; Brell, J.; Savvides, P.; Krishnamurthi, S.; Bokar, J.; Horvath, N.; Ness, A.; Remick, S. Phase I Pyronaridine Tetraphosphate trial of daily lenalidomide and docetaxel given every three weeks in patients with advanced solid tumors. 2008, Abstract # 189. REFERENCES 1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin. 2007;57:43C66. [PubMed] [Google Scholar] 2. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971;285:1182C1186. [PubMed] [Google Scholar] 3. Weidner N, Folkman J. Tumoral vascularity as a prognostic factor Pyronaridine Tetraphosphate in Pyronaridine Tetraphosphate cancer. Important Adv. Oncol. 1996:167C190. [PubMed] [Google Scholar] 4. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast arcinoma. J. Natl. Cancer Inst. 1992;84:1875C1887. [PubMed] [Google Scholar] 5. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N. Engl. J. Med. 1991;324:1C8. [PubMed] [Google Scholar] 6. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 1993;143:401C409. [PMC free article] [PubMed] [Google Scholar] 7. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist. 2007;12:356C361. [PubMed] [Google Scholar] 8. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007;12:713C718. [PubMed] [Google Scholar] 9. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353C364. [PubMed] [Google Scholar] 10. Strohmeyer D, Rossing C, Strauss F, Bauerfeind A, Kaufmann O, Loening S. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate. 2000;42:26C33. [PubMed] [Google Scholar] 11. Gettman MT, Pacelli A, Slezak J, Bergstralh EJ, Blute M, Zincke H, Bostwick DG. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology. 1999;54:479C485. [PubMed] [Google Scholar] 12. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Kruger EA, Gubish E, Pluda JM, Reed E. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res. 2001;7:1888C1893. [PubMed] [Google Scholar] 13. Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate EPLG6 cancer. Semin. Oncol. 2001;28:62C66. [PubMed] [Google Scholar] 14. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J. Clin. Oncol. 2004;22:2532C2539. [PubMed] [Google Scholar] 15. Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut W. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int. 2007;99:1047C1055. [PubMed] [Google Scholar] 16. Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb. Haemost. 2001;86:23C33. [PubMed] [Google Scholar] 17. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent.